Artal Group’s Agilon Health AGL Stock Holding History

Artal Group’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,000	Closed	-$12.2M	–	147
2021 Q2	$12.2M	Buy	+12,000	New	+$10.5M	0.25%	81

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Artal Group's AGL Position: Q3 2021 in Review

Artal Group sold out of Agilon Health (AGL) in Q3 2021, closing a stake of 12,000 shares — an estimated $12.2M sold.

Artal Group first reported a position in AGL in Q2 2021 and held it in 1 quarter. The position peaked at $12.2M in Q2 2021. 102 funds tracked by Wall St. Rank hold AGL as of Q3 2021.

Artal Group reported no remaining Agilon Health position as of Q3 2021 after selling out during the quarter.
Artal Group sold 12,000 Agilon Health shares in Q3 2021, an estimated $12.2M.
Artal Group first reported a position in Agilon Health in Q2 2021 and held it in 1 quarter.
Artal Group's Agilon Health position peaked at $12.2M in Q2 2021.
102 funds tracked by Wall St. Rank held Agilon Health as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.